Top broker predicts 14% upside for CSL share price

Brokers are giving CSL shares a thumbs up right now.

| More on:
Woman flexes muscles after donating blood.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investors who own CSL Ltd (ASX: CSL) shares are probably not a happy bunch right now. The ASX 200 healthcare giant has been stuck in the mud for a long time now – share price-wise, that is.

Today, CSL shares are trading at $276.52 at the time of writing, up 0.56% for the day thus far.

At this share price, CSL has gone backwards by 8.55% over the last 12 months and remains down 4.1% in 2024 to date.

It also means that CSL shares haven't gone anywhere for almost four years now. Yep, if you bought CSL back in May of 2020, you would have paid a similar price to what's being offered today.

The past four years are a very different story from what investors enjoyed over the four years before that. Between 2016 and 2020, CSL shot the lights out, shooting up from just over $100 a share to over $300.

Check all that out for yourself below:

Of course, there have been dividend payments to keep investors company during the past four-year drought. But CSL has never been a solid dividend payer, and today offers a dividend yield of 1.18%. Since May of 2020, CSL investors might have even done better keeping their money in a term deposit, rather than in CSL shares.

But all that is about to change, at least if one ASX expert is to be believed.

ASX experts rate CSL shares as a buy

As reported by The Bull, Damien Nguyen, analyst at ASX broker Morgans, has just given CSL a buy rating. Nguyen also gave the healthcare stock a 12-month share price target of $315.40. If realised, that would see investors enjoy a return of just over 14% over the coming year. Now that would be better than a term deposit.

Here's what Nguyen had to say on CSL shares:

The blood products group's first half results in fiscal year 2024 were broadly in line with expectations. Total revenue of $US8.053 billion was up 12 per cent on the prior corresponding period. Reported net profit after tax of $US1.901 billion from ordinary activities was up 17 per cent.

Unmet demand across all divisions provides confidence that management is likely to achieve double-digit earnings growth over the medium term. Our 12-month price target is $315.40…

A company's share price tends to follow its earnings over time. So "double-digit earnings growth over the medium term" is exactly what shareholders will probably want to hear is allegedly in store for CSL.

But Morgans isn't the only expert expecting good things from CSL shares going forward. Earlier this month, my Fool colleague James looked at the views of another ASX broker in UBS. Its analysts are also expecting "double-digit earnings growth over the coming years". Accordingly, UBS gave CSL a buy rating, alongside a 12-month share price target of $330.

So it appears these two brokers are united in a positive outlook for this ASX 200 healthcare giant. But let's see what happens with CSL shares going forward.

Motley Fool contributor Sebastian Bowen has positions in CSL. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has recommended CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

two doctors smile as they sit together at a desk looking at a patient's Xray.
Healthcare Shares

This ASX 200 healthcare stock just hit an all-time high: Is it too late to buy?

The valuation of this high-performer has soared.

Read more »

A smiling woman sits in a cafe reading a story on her phone about Rio Tinto and drinking a coffee with a laptop open in front of her.
Healthcare Shares

1 magnificent ASX stock down 10% to buy and hold forever

Analysts say this high-quality stock is a great option for investors right now.

Read more »

ventilator mask
Healthcare Shares

3 reasons ResMed shares 'are just too cheap!'

This stock could still produce healthy gains, according to one fund manager.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

2 ASX healthcare shares rocking higher on big news

This 'spray-on skin' company and cancer-fighting biotech have exciting news for shareholders today.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

Insider still buying Mesoblast shares despite 230% rise this year: Should you buy?

This high-flying share is still reporting insider buying. Should you buy too?

Read more »

A woman reclines in a comfortable chair while she donates blood holding a pumping toy in one hand and giving the thumbs up in the other as she is attached to a medical machine to collect her blood donation.
Healthcare Shares

Buy CSL shares for growing dividends and 'compelling long-term tailwinds'

CSL has increased both its interim and final dividend every year since 2021.

Read more »

a doctor in a white coat makes a heart shape with his hands and holds it over his chest where his heart is placed.
Healthcare Shares

Resmed share price higher despite CEO hitting sell on 14,683 shares

ResMed's CEO just sold $4.8 million worth of his own company's shares.

Read more »

Scientist looking at a laptop thinking about the share price performance.
Healthcare Shares

Why this high-flying ASX 200 healthcare stock just crashed 11%

Neuren Pharmaceuticals just dropped its 1Q FY24 report on DAYBUE sales.

Read more »